Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
AI Sentiment
Highly Positive
9/10
as of 12-26-2025 2:10pm EST
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 8.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 141.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.11 - $10.16 | Next Earning Date: | 01-13-2026 |
| Revenue: | $4,884,000 | Revenue Growth: | -11.35% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
BMRA Breaking Stock News: Dive into BMRA Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
9/10
See how BMRA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BMRA Biomerica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.